Inagen Aps inagen.com


Public lists: Pharma Startups (4732)

Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.

Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.

Company (Alive / Active)

Phone:

Fax:

150 Allens Creek Road
Rochester, 14618
New York, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Inagen Aps $0M Nov 30, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Inagen Aps Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Intarcia Therapeutics

Boston, Massachusetts, United States
Alive / ActiveIntarcia Therapeutics is a biopharmaceutical company developing therapies to ensure the best treatment outcome by optimizing patient convenience and adherence. Intarcia is addressing challenging diseases that require long-term chronic therapy by enhancing efficacy and reducing the burden therapies often place on the patient's life. Intarcia's drug development expertise and competitive edge is demonstrated by its ability to stabilize macromolecules and to deliver them in a constant and consistent...Show allLogin to see details

GlobeImmune

Louisville, Colorado, United States
IPO / Went publicGlobeImmune is a biopharmaceutical company focused on developing products for the treatment of infectious disease and and oncology based on its proprietary Tarmogen platform. Tarmogens are believed to activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications an...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Immunotoxins for the treatment of diseases related to cmv infection Jul 03, 2007 Nov 26, 2013 Patent